ADDF-Harrington Scholar award focuses on Alzheimer's/dementia breakthroughs with commercial viability. Eniola's CCT model is an addiction-neuroscience mechanism, not dementia-specific; the fit requires an explicit bridge (e.g. shared synaptic-plasticity/consolidation mechanisms) rather than a direct match. Do not cite IMPRINT/GATE as built platforms; her real portfolio is CCT, TOPOLOGIX (ESM-2 pivot), neurocascade, ergofluids.